Moderate Evidence
Research Overview
CT-388 Research for Type 2 Diabetes
An evidence-based overview of research examining CT-388 in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
The GLP-1/GIP dual agonist mechanism has proven effective for glycemic control with tirzepatide. CT-388 is expected to have similar glucose-lowering effects through enhanced insulin secretion and improved insulin sensitivity. Phase 2 trials in T2D are planned or ongoing.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Type 2 Diabetes
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. CT-388 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.